Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL91356 | 0.85 | TAAR1 (0.50) | TAAR1KDM4EAKR1B1LMNASMN1; SMN2 | |
| SCHEMBL18568047 | 0.82 | TAAR1 (0.45) | TAAR1KDM4EAKR1B1LMNAPKM | |
| SCHEMBL597056 | 0.82 | CYP2A6 (0.45) | TAAR1ALDH1A1NOS3NOS2 | |
| SCHEMBL13473756 | 0.81 | PLA2G7 (0.41) | TAAR1KDM4ELMNAPKMP2RX7 | |
| SCHEMBL9861759 | 0.81 | TAAR1 (0.43) | TAAR1KDM4EAKR1B1LMNAPKM | |
| SCHEMBL20749239 | 0.80 | CFTR (0.44) | TAAR1KDM4EAKR1B1LMNAPKM | |
| SCHEMBL14363074 | 0.79 | IDO1 (0.43) | TAAR1KDM4EAKR1B1LMNAPKM | |
| SCHEMBL14567074 | 0.79 | TAAR1 (0.41) | TAAR1KDM4EAKR1B1LMNAPKM | |
| SCHEMBL6358890 | 0.79 | TAAR1 (0.41) | TAAR1KDM4EAKR1B1LMNAPKM | |
| SCHEMBL14127124 | 0.79 | TAAR1 (0.41) | TAAR1KDM4EAKR1B1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4729040-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| EP-1761574-A1 | POLYMERIZATION PROCESS USING HYDROFLUOROCARBONS | ExxonMobil Chemical Patents Inc. (US) | 2007-03-14 | — | — | EP | claimed |
| WO-2006011868-A1 | POLYMERIZATION PROCESSES USING HYDROFLUOROCARBONS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-4140695-A | Process for producing copper phthalocyanines | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1979-02-20 | — | — | US | claimed |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2024-07-18 | — | — | US | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| WO-2024077391-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIVERSITE DE MONTREAL (CA) | 2024-04-18 | — | — | WO | disclosed |
| US-20230399307-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399315-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | AMYGDALA NEUROSCIENCES, INC. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230271943-A1 | COMPOUNDS AS DHODH INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007138110-A2 | COMPOUNDS THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY | DEVGEN N.V. (BE) | 2007-12-06 | — | — | WO | disclosed |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070225334-A1 | Methods for treating cognitive and other disorders | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-7226950-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-5157182-A | Conversion of ortho-ethyltoluene to indene | AMOCO CORPORATION (US) | 1992-10-20 | — | — | US | disclosed |
| US-4140695-A | Process for producing copper phthalocyanines | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399315-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | ALDH1A1, ALDH2, ALDH3A1 | TAAR1 146/4885KDM4E 924/4885AKR1B1 172/4885 |
| US-20230399307-A1 | ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE | ALDH1A1, ALDH2, ALDH3A1 | TAAR1 132/4885KDM4E 970/4885AKR1B1 190/4885 |
| US-20070225334-A1 | Methods for treating cognitive and other disorders | CHAT, COMT, ACHE | TAAR1 490/4885KDM4E 1655/4885AKR1B1 481/4885 |
| US-20230271943-A1 | COMPOUNDS AS DHODH INHIBITORS | DHODH, DLD, DHRS9 | TAAR1 4107/4885KDM4E 2099/4885AKR1B1 184/4885 |
| US-20240239801-A1 | PYRIMIDO[5,4,D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, BRAF, KRAS | TAAR1 3437/4885KDM4E 2695/4885AKR1B1 1201/4885 |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | TBXA2R, HTR2C, NPY1R | TAAR1 64/4885KDM4E 2362/4885AKR1B1 610/4885 |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, DPYD | TAAR1 3353/4885KDM4E 2840/4885AKR1B1 619/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | TAAR1 2965/4885KDM4E 201/4885AKR1B1 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.